Cardiovascular diseases (CVDs) remain a leading cause of death worldwide. More than half of the patients suffering from heart failure (HF) have coexisting comorbidities such as obesity, diabetes mellitus, hypertension. Amongst the comorbidities, the emerging prevalence of non-alcoholic fatty liver disease (NAFLD), which is associated with an increased risk of cardiovascular events, has led us to urgently focus on this therapeutic area. Moreover, the local and systemic inflammation observed in metabolic and vascular abnormalities have paved the way for the development of new pharmacological strategies.
Cardiomedex’s mission is to perform tailor-made preclinical studies in the field of cardiovascular and cardiometabolic diseases . Our comprehensive studies deliver key mechanistic data and help eliminate the risk of cardiac safety issues of drugs before they hit the pipeline or clinical trials.
Cardiomedex offers benchmarked predictive animal models that mimic the human situation and in vivo exploration to provide in-depth functional characterization. Moreover, thanks to a highly skilled team, we are able to develop new preclinical models based on emerging areas to fulfil our clients’ needs.
Heart failure with preserved ejection fraction (HFpEF)
The incidence of HFpEF, also called diastolic heart failure, has increased rapidly over the past few decades and is becoming the most prevalent form of heart failure. HFpEF, for which there is no specific treatment, is characterized along with diastolic dysfunction, by numerous non-cardiac comorbidities such as obesity, diabetes mellitus, NASH, which adversely affect prognosis. As HF care recommendations are increasingly targeting the treatment of comorbidities, Cardiomedex provides relevant models with multi-risk factors, as observed in clinical situations.
Models with concomitant obesity, insulin resistance and NASH are developed in collaboration with Physiogenex and metabolic characterization is available on their website (animals already on diet are available).
HFpEF /NASH-HamsterHFpEF /Angiotensin II – MouseHFpEF / NASH – MouseHFpEF /Obesity – RatHFpEF /Diabetic nephropathy – Rat
Myocardial Infarction induced heart failure with reduced ejection fraction (HFrEF)
Myocardial infarction is a key component of cardiovascular disorders, which makes it the most prevalent CVD in the western world. Myocardial infarction leads to heart failure when it is inadequately managed. In this case, cardiac output is greatly reduced and the aetiology refers to heart failure with reduced ejection fraction.
Cardiomedex provides rat and mouse models of chronic cardiac ischemia induced by permanent coronary artery ligation
Acute myocardial infarction - Ischemia reperfusion injury
Acute myocardial infarction, commonly known as a heart attack, is considered part of a spectrum referred to as acute coronary syndrome (ACS). Interruption of the blood supply to part of the heart leads to death or necrosis of myocardial cells when myocardial ischemia exceeds a critical threshold and overwhelms myocardial cellular repair mechanisms designed to maintain normal heart physiology.Acute MI – Rat & Mouse
Cardiac hypertrophy is a major predictor of many cardiovascular diseases including heart failure with ominous prognosis. Cardiac hypertrophy is an adaptive response usually driven by a larger workload through either biomechanical stretch‐sensitive mechanisms or neurohumoral activation. Our dedicated experimental models are instrumental in furthering the understanding of cardiac hypertrophy pathophysiology and evaluating drugs candidates.
Cardiomedex provides the gold standard pressure-overload model induced by controlled transverse aortic constriction (TAC), and the angiotensin-II induced hypertrophy model.
Aortic constriction – RatAortic constriction – MouseAngiotensin II – Mouse
Cardiovascular complications - Cardiometabolic models
Over the past few decades, there has been a dramatic increase in cardiometabolic complications including hyperlipidemia, dyslipidemia, obesity, type 2 diabetes, hypertension, nephropathy and non-alcoholic fatty liver disease not only in industrialized nations but also in developing nations with emerging economies. These cardiovascular and metabolic disorders, both individually and interdependently, have led to a substantial increase in CVD morbidity and mortality. The selective prevention of cardiometabolic complications could help reduce the burden of these diseases in the general population,
With this objective, Cardiomedex, in association with Physiogenex provides relevant models with concomitant risk factors with full cardiovascular characterization.
Hypertension is the most common cardiovascular disease and can lead to lethal complications if left untreated. Indeed, hypertension is one of the highest risk factors for almost all the different cardiovascular diseases acquired during a person’s lifetime (coronary disease, left ventricular hypertrophy, renal failure…).
Experimental models (genetic, surgical or dietary) are provided for unraveling the pathogenesis of hypertension and for testing novel therapeutic strategies.Genetic Hypertension – Rat (SHR rats)
Doxorubicin-induced cardiotoxicity or other related agents inducing heart or vascular toxicity
The anthracyclines, one of the most common classes of chemotherapeutic agents, have been widely associated with an increased risk of cardiac toxicity limiting their used as anticancer treatment.
For this purpose, we provide both acute and chronic models of doxorubicin cardiotoxicity to investigate cardioprotective effects of drug candidates.
Sepsis is a systemic inflammatory response that follows bacterial infection and can lead to severe sepsis and septic shock characterized by hypotension, ischemia, multiple organ failure, and death. Sepsis is a major health complication causing patient mortality and rising health care costs.
Animal models are currently in development to create reproducible systems for studying sepsis pathogenesis and preliminary testing of potential therapeutic agents.
For all models, biochemical assays and histology analysis are available to fully characterize your drug candidates’ mechanism of action and potential:
Lactic acid – lactate dehydrogenase
Cholesterol, triglycerides, fatty acids
Hematology – Complete blood count
Red blood cells and their percentage (hematocrit) or protein content (hemoglobin), white blood cells, and platelets
ELISA and multiplex assays:
Hormones (pro-BNP, troponin I, insulin, etc.)
Cytokines / chemokines panel (IL-1β, IL-6, MCP-1, TNFα, IFNγ, MIP-1α/ β; MIP-2, RANTES… etc.)
Western Blot analysis (WES technology): for any protein, on any sample/tissue.
Protein (western blot) and Gene (qPCR) expression on any tissue:
Glucose/fatty acid metabolism
ER and oxidative stress
Haematoxylin & Eosin
Immunohistochemistry (WGA, collagen III, alpha-SMA, etc.)
CONTACT US FOR MORE INFORMATION